AstraZeneca Group Revenue Growth: 3.99%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AZN Revenue Growth Rankings
| Overall | 39th percentile | 2659 of 4424 |
| Sector | 38th percentile | 285 of 464 in Healthcare |
| Industry | 40th percentile | 12 of 20 in Drug Manufacturers - Major |
AZN Revenue Growth Range, Past 5 Years
| Minimum | -13.20% | Mar 2001 |
| Maximum | 19.21% | Jun 2004 |
| Average | 7.92% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these AZN related companies
AZN News
AstraZeneca (AZN) Broadens AZ&Me Prescription Savings Programs Eligibility
Feb 08, 9:01AM Street Insider
Feb 08, 9:01AM Street Insider
AstraZeneca US Broadens Income Eligibility for Prescription Savings Programs
Feb 08, 9:00AM Business Wire
Feb 08, 9:00AM Business Wire
RT @bradloncar Not impressed w big share buyback $AZN is planning for 2012. Won't help investrs much if they dont figure out innovation soon
about 10 days ago by wallstreetbean
about 10 days ago by wallstreetbean
R&D in Quebec pharma industry continues to erode $AZN $JNJ $SNY $MRK
about 10 days ago by michaelbabad
about 10 days ago by michaelbabad
AstraZeneca (AZN) Announces Restructuring, Will Eliminate 7,300 Positions
Feb 02, 7:18AM Street Insider
Feb 02, 7:18AM Street Insider
RT @wallstreetbean $IPXL "Impax acquires US rights to migraine drug Zomig" http://stks.co/2CIn will pay $AZN $130M and royalties.
about 11 days ago by STheadlines
about 11 days ago by STheadlines
Notable #EarningsReports AfterHours: $CMG $LVS $QCOM $GMCR $TSCO $JDSU PreMarket: $ADS $MA $RGLD $ODFL $AZN $BZH #LeadingStocks #StockMarket
about 11 days ago by CapitalistBull
about 11 days ago by CapitalistBull
Impax (IPXL) Unit Licenses Zomig Rights in U.S. from AstraZeneca (AZN); Updates FY12 Outlook
Feb 01, 8:07AM Street Insider
Feb 01, 8:07AM Street Insider
Impax Labs $IPXL licenses exclusive US commercialization to Zomig from AstraZeneca $AZN, to pay $130M
about 11 days ago by Street_Insider
about 11 days ago by Street_Insider
Impax Labs (IPXL) licenses exclusive US commercialization to Zomig from AstraZeneca (AZN)
Feb 01, 8:01AM Street Insider
Feb 01, 8:01AM Street Insider
@insidermonkey Afternoon Aggregate News: Hedge Funds Took In $3.6 Billion In November, Lampert Cuts $AZN $SHLD http://stks.co/1m1H $AIG $C
about 39 days ago by valuewalk
about 39 days ago by valuewalk
$E, $BMA, $PBR, $AZN 10 picks from a master contrarian http://stks.co/1c0x
about 55 days ago by eyeonequities
about 55 days ago by eyeonequities
$AZN says it's cutting its U.S. sales force by about 24% as part of the company's recent efforts to cut costs.
about 67 days ago by NCFinanceGuy
about 67 days ago by NCFinanceGuy
7 Stocks Hussman Strategic Growth Fund http://stks.co/1PcG $AZN $BIIB $ENDP $HUM $KO $LIFE $PNRA
about 68 days ago by myplaniq
about 68 days ago by myplaniq
$AZO RT @Briefingcom AutoZone Beats First Quarter Expectations http://stks.co/1PEt $AZN
about 68 days ago by wallstreetbean
about 68 days ago by wallstreetbean
@yukikobayashi $TRGT will be back to $10 for sure in a month. Look at the option volume December 17th. $TRGT has cash, $AZN is their back!
about 93 days ago by yukikobayashi
about 93 days ago by yukikobayashi
$AZN 50 Day SMA Cross - Price crossed below 50 day SMA (46.0094). Confirmed by volume.
about 95 days ago by TradeIdeasQuant
about 95 days ago by TradeIdeasQuant
$AZN depression a tricky thing to treat. Was worthwhile, but risky bet. Still other studies to complete with TC-5214 though...may be viable.
about 96 days ago by wallstreetbean
about 96 days ago by wallstreetbean
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AZN | 47.16 | -0.33 | -0.69% | 63.44B |
| XIN | 2.36 | -0.08 | -3.28% | 180.54M |
| IMN | 6.09 | -0.07 | -1.14% | 232.15M |
| AGM | 20.40 | -0.54 | -2.58% | 211.14M |
| DEG | 55.87 | -1.03 | -1.81% | 5.69B |
| SHLD | 47.57 | -0.82 | -1.69% | 5.09B |
| WFT | 17.79 | -0.41 | -2.25% | 13.33B |
| HMIN | 31.06 | -0.31 | -0.99% | 1.23B |
| ANR | 21.04 | -1.36 | -6.07% | 4.76B |
| HEB | 0.37 | 0.04 | 10.45% | 50.13M |
